AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17900321
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of a multispecies probiotic, Ecologic AAD (10(9) cfu/g), twice daily for 14 days
Trial: 16231754
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of morning home blood pressure in patients taking antihypertensive drugs
Trial: 10088180
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no calcitriol treatment)
Trial: 8527710
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 600 mg orally per day for 6 months
Trial: 7190412
Drug: Clofibate and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofibate and biguanide treatment
Trial: 30115068
Drug: Plant extract
RxNorm normalized name: Plant extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant extract based supplement
Trial: 26831610
Drug: Telmisartan 40/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 40/80 mg once daily with lifestyle modification (TL)
Trial: 26831610
Drug: Lifestyle modification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle modification (L)
Trial: 23362618
Drug: Low-dose MF59-adjuvanted
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose MF59-adjuvanted A/H5N1 vaccine (3.75 μg)
Trial: 23362618
Drug: Licensed higher-dose
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Licensed higher-dose A/H5N1 vaccine (7.5 mg)
Trial: 23362618
Drug: Both vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccines (low-dose and licensed)
Trial: 19573142
Drug: Specific Oral
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific Oral Tolerance Induction (SOTI)
Trial: 16834647
Drug: Periprostatic lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periprostatic lidocaine injection (5 mL of 2% lidocaine solution injected near the junction of the seminal vesicle with the base of the prostate)
Trial: 16834647
Drug: Intrarectal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal lidocaine gel (20 mL of 2% lidocaine gel intrarectally)
Trial: 16834647
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline injection (5 mL normal saline injected along the neurovascular bundles)
Trial: 10574640
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg chlormadinone acetate
Trial: 8623152
Drug: Cyclosporine emulsion
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine emulsion capsules
Trial: 8623152
Drug: Cyclosporine (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (oral solution for microemulsion)
Trial: 1778088
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg diclofenac dispersible 3-times daily for 4 weeks
Trial: 1778088
Drug: Placebo 3-times
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 3-times daily for 4 weeks
Trial: 1778088
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg diclofenac dispersible
Trial: 29523524
Drug: Chlorthalidone (thiazide-like
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (thiazide-like diuretic)
Trial: 25832522
Drug: Heroin-assisted treatment
RxNorm normalized name: heroin
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heroin-assisted treatment (HAT) for 12 months
Trial: 25832522
Drug: Methadone maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone maintenance treatment (Control)
Trial: 23524942
Drug: Cisplatin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (75 mg/m2 on days 1 and 2) and capecitabine (750 mg/m2 in two divided doses from day 1-14)
Trial: 23524942
Drug: Cisplatin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (75 mg/m2 on days 1 and 2) and 5-FU (750 mg/m2 on days 1, 2, and 3)
Trial: 19671877
Drug: ipilimumab with
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ipilimumab with daily blinded budesonide (group A)
Trial: 9466064
Drug: Neomycin/dexamethasone spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neomycin/dexamethasone spray (Otomize)
Trial: 8192128
Drug: Treatment attendance
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment attendance
Trial: 25602857
Drug: Exercise-based cardiac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise-based cardiac rehabilitation (ECR) consisting of 8 weeks of aerobic exercise at 70-85% of maximal heart rate during 3 sessions weekly plus usual care
Trial: 23777763
Drug: post‐rVWF‐rFVIII infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: post‐rVWF‐rFVIII infusion
Trial: 8996345
Drug: 200 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms desmopressin tablets
Trial: 8996345
Drug: 400 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 micrograms desmopressin tablets
Trial: 8996345
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms nasal spray
Trial: 8996345
Drug: Desmopressin tablets
RxNorm normalized name: desmopressin Sublingual Tablet
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Desmopressin tablets (both doses)
Trial: 8424470
Drug: Nortriptyline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline (100 mg median nightly dose for 6 weeks)
Trial: 3307548
Drug: Propanidid (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propanidid (9 mg X kg‐1 IVD, and 60 mg X kg‐1 X h‐1)
Trial: 3307548
Drug: Propofol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2.5 mg X kg‐1 IVD, and 9 mg X kg‐1 X h‐1)
Trial: 29466550
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment (Van Riper, 1939)
Trial: 22562977
Drug: adalimumab therapy
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: adalimumab therapy
Trial: 20581215
Drug: Pregabalin 50
RxNorm normalized name: pregabalin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 50 mg, Pregabalin 75 mg, Placebo
Trial: 15935272
Drug: Metal-free polymer
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metal-free polymer crowns with chamfer finishing line or shoulder preparation
Trial: 11826695
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 2% xylocaine with 1:80,000 epinephrine
Trial: 9893655
Drug: Primary chemotherapy
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary chemotherapy (FEC: 5‐fluorouracil 600 mg/m2, epidoxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2)
Trial: 9893655
Drug: Pathological complete
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pathological complete response after induction treatment
Trial: 9893655
Drug: Low [3H]‐dT‐LI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low [3H]‐dT‐LI after primary chemotherapy
Trial: 9893655
Drug: Bcl-2 expression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bcl-2 expression before primary chemotherapy
Trial: 9893655
Drug: Bcl-2 expression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bcl-2 expression after primary chemotherapy
Trial: 3277083
Drug: Clonazepam (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam (0.25 to 0.5 mg/d)
Trial: 23097067
Drug: Sildenafil (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (target dose 40 mg three times per day)
Trial: 10757621
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion (50 pmol/kg x h)
Trial: 8818093
Drug: Tea (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tea (150 ml)
Trial: 8818093
Drug: Apple juice
RxNorm normalized name: apple juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple juice (150 ml)
Trial: 1446762
Drug: Hyaluronidase (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyaluronidase (50 i.u./ml) and adrenaline (1:200,000)
Trial: 27351245
Drug: Curcumin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (500 mg/day)
Trial: 25881813
Drug: Routine methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine methods plus dietary sweet potato consumption (200 g/d from admission to discharge)
Trial: 17383174
Drug: Topical vitamin
RxNorm normalized name: vitamin A Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical vitamin E (800 mg)
Trial: 7852539
Drug: Benfluorex (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benfluorex (150 mg) three times daily for 6 weeks
Trial: 26712981
Drug: IV clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV clonidine 4 µg/kg
Trial: 26712981
Drug: IV clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV clonidine 5 µg/kg
Trial: 26712981
Drug: IV clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV clonidine 3 µg/kg
Trial: 22338149
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg rituximab weekly for 4 weeks (group A)
Trial: 22338149
Drug: 375 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg/m2 rituximab single dose (group B)
Trial: 19662727
Drug: ProTaper canal
RxNorm normalized name: Canalevia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProTaper canal preparation and single cone obturation with matching gutta‐percha point
Trial: 19662727
Drug: ProTaper preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProTaper preparation plus thermoplastic obturation (Thermafil)
Trial: 19662727
Drug: Profile .06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Profile .06 taper and matching master cone with lateral condensation
Trial: 17931541
Drug: Preprinted medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preprinted medication labels
Trial: 17931541
Drug: Blank medication
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blank medication labels
Trial: 15355745
Drug: Tumor necrosis
RxNorm normalized name: Tumor necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor necrosis factor blocking agents
Trial: 3322537
Drug: 6-hydroxybenzo[b]thiophene-2-sulfonamide, 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-hydroxybenzo[b]thiophene-2-sulfonamide, 2% suspension, administered twice daily for 1 week to one eye
Trial: 3322537
Drug: Placebo drop,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drop, administered twice daily for 1 week to one eye
Trial: 22014807
Drug: Toremifene 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene 80 mg by mouth daily
Trial: 19151449
Drug: Curcumin low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin low dose (3 times 15 mg/day)
Trial: 19151449
Drug: Curcumin moderate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin moderate dose (3 times 30 mg/day)
Trial: 19151449
Drug: Curcumin high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin high dose (3 times 60 mg/day)
Trial: 19151449
Drug: Curcumin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (all doses)
Trial: 16531903
Drug: 2.5 mg.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg.kg(‐1) bw pseudoephedrine
Trial: 16531903
Drug: 2.5 mg.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg.kg(‐1) bw maltodextrins (placebo)
Trial: 14625607
Drug: Percutaneous hydrochloric
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous hydrochloric acid injection (PHI)
Trial: 11084175
Drug: Continuous regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous regimen of oral conjugated equine estrogens (CEE), 0.625 mg/day, combined with medroxyprogesterone acetate (MPA), 5.0 mg/day
Trial: 11084175
Drug: Continuous regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous regimen of oral conjugated equine estrogens (CEE), 0.625 mg/day, combined with medroxyprogesterone acetate (MPA), 2.5 mg/day
Trial: 31047790
Drug: PT followed
RxNorm normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PT followed by an increased dose of PT (PT-PT)
Trial: 31047790
Drug: CBT followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CBT followed by an increased dose of CBT (CBT-CBT)
Trial: 28643374
Drug: LY2510924 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2510924 (20 mg once daily)
Trial: 28643374
Drug: LY2510924 (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2510924 (subcutaneous administration)
Trial: 9803103
Drug: 23 G
RxNorm normalized name: PEG-23 GLYCERYL DISTEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23 G needle
Trial: 22951158
Drug: blood‐based crisp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blood‐based crisp bread (35 mg of iron, 27 mg heme Fe)
Trial: 22951158
Drug: iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iron supplementation (35 mg of non‐heme iron/day)
Trial: 22951158
Drug: iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iron supplementation (60 mg of non‐heme iron/day)
Trial: 22951158
Drug: control (iron‐free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control (iron‐free tablets)
Trial: 21272186
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + pioglitazone 45 mg (n = 12)
Trial: 21272186
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy alone (n = 13)
Trial: 19039237
Drug: Low-dose GH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose GH for 2 years (0.033/0.033 mg/kg/day, n = 51)
Trial: 19039237
Drug: High-dose GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose GH for 1 year and then no treatment for 1 year (0.100/0 mg/kg/day, n = 51)
Trial: 19039237
Drug: Mid-dose GH
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid-dose GH for 1 year (0/0.067 mg/kg/day, n = 47)
Trial: 19039237
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of high-dose and low-dose GH after 2 years
Trial: 17697905
Drug: SKI306X 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKI306X 200 mg TID
Trial: 11986726
Drug: New inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New inactivated HAV vaccine (1000 units)
Trial: 2644795
Drug: Intravenous propafenone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propafenone, 2 mg/kg over 10 minutes
Trial: 401600
Drug: Glucagon (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon (2 mg)
Trial: 766062
Drug: Pro‐Banthine (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pro‐Banthine (45 mg)
Trial: 31280348
Drug: High-dose bortezomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose bortezomib (1.6 mg/m2) with dexamethasone and cyclophosphamide
Trial: 31280348
Drug: Low-dose bortezomib
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose bortezomib (1.3 mg/m2) with dexamethasone and cyclophosphamide
Trial: 31280348
Drug: High-dose bortezomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose bortezomib (1.6 mg/m2)
Trial: 31280348
Drug: High-dose bortezomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose bortezomib (1.6 mg/m2) and low-dose bortezomib (1.3 mg/m2)
Trial: 22935739
Drug: Aerobic Interval
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic Interval Training (AIT) with caffeine (3 mg·kg(‐1))
Trial: 22935739
Drug: Resting with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resting with caffeine (3 mg·kg(‐1))
Trial: 21450707
Drug: Bilateral insertion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral insertion of 0.20×15 mm Seirin needles to 12 mm depth at ST36, daily treatments of 30 s duration for three consecutive workdays
Trial: 17900887
Drug: SFC (S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFC (S 50 mcg/FP 250 mcg b.i.d.)
Trial: 17900887
Drug: S+FP (S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S+FP (S 50 mcg b.i.d.+FP 250 mcg b.i.d.)
Trial: 11985192
Drug: Tooth brushing
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tooth brushing and 0.2% NaF weekly mouthwashes (Control group, n=33)
Trial: 31072314
Drug: EBRT (External
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBRT (External Beam Radiotherapy) with either 30 Gy in 10 fractions or 8 Gy as a single dose
Trial: 26761967
Drug: Nicorandil in
RxNorm normalized name: Product containing nicorandil in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil in addition to standard therapy (aspirin, rosuvastatin, valsartan, bisoprolol)
Trial: 26761967
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (aspirin, rosuvastatin, valsartan, bisoprolol)
Trial: 23317561
Drug: Oral meprednisone
RxNorm normalized name: Meprednisone
DrugBank: Meprednisone acetate (DB14625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral meprednisone preoperatively
Trial: 23317561
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no preoperative systemic steroids)
Trial: 22021510
Drug: Low-dose chest
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose chest CT examination
Trial: 22021510
Drug: Low-dose chest
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose chest CT examination (using ICRP 60 tissue-weighting factors)
Trial: 22021510
Drug: Low-dose chest
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose chest CT examination (using ICRP 103 tissue-weighting factors)
Trial: 18835927
Drug: Fluoxetine (6-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (6-week administration)
Trial: 11278212
Drug: Low-dose step-up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose step-up regimen (starting dose 75 IU)
Trial: 11278212
Drug: Modified step-down
RxNorm normalized name: Kool-Down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified step-down regimen (starting dose 300 IU, followed by 3 days free of treatment, then 75 IU daily)
Trial: 9042530
Drug: Dim Light‐Caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim Light‐Caffeine (200 mg twice each night)
Trial: 27651510
Drug: Manipulated high-volume
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulated high-volume morphine-ADER-IMT (60 mg)
Trial: 27651510
Drug: Manipulated low-volume
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulated low-volume morphine-ADER-IMT (60 mg)
Trial: 27651510
Drug: Intact oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact oral morphine-ADER-IMT (60 mg)
Trial: 27651510
Drug: Manipulated low-volume
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulated low-volume morphine ER (60 mg)
Trial: 11342682
Drug: lamotrigine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lamotrigine (150 mg/day)
Trial: 11342682
Drug: carbamazepine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carbamazepine (mean 696 mg/day)
Trial: 8149032
Drug: 5 milligrams
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 milligrams per kilogram per minute of glucose infusion during preoperative overnight fasting
Trial: 8149032
Drug: No infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No infusion (control group) during preoperative overnight fasting
Trial: 25782429
Drug: Daily fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily fruit consumption